视网膜萎缩衡量光学相干断层扫描预测残疾进展在多发性硬化(S45.007)

文摘

目的:探讨视神经盘旁视网膜神经纤维层的作用(pRNFL)厚度或黄斑体积(MV),在眼睛不受(non-ON眼),作为一个预测多发性硬化(MS)患者的残疾进展。背景:逆协会non-ON视网膜厚度之间的眼睛和残疾女士之前已经报道过了。然而,明确纵向证据表明视网膜厚度的变化作为一个有效的代理端点的残疾女士的进展仍然缺乏。设计/方法:在这项研究中,我们招收了879名患者的临床随访确定五年(739年临床孤立综合征或复发汇款女士,和141年进步MS)。残疾进展评估使用规模扩大残疾状况。pRNFL厚度和MV的平均值计算non-ON眼睛。我们执行比例风险模型来估计pRNFL厚度之间的关系和MV,残疾的风险过程,调整年龄、疾病持续时间、基线残疾,疾病修饰治疗方法的使用。结果:残疾发展于252年指出879 (28.5 [percnt])患者的随访时间是2.32年。MS患者prnfl92s - 93 cμm (S: Spectralis;C:卷)厚度non-ON眼睛与58 (percnt)的风险增加相关残疾进展相比,患者pRNFL > 92年代- 93 cμm后在任何时间确定在这个队列的第一年(HR = 1.582 95 [percnt] CI (1.133 - -2.208); p=0.007]. Further, a pRNFL<87C-88Sμm doubled the risk of disability progression at any time during the second and third year of follow-up [HR=2.055 95[percnt]CI(1.356-3.114); p=0.001], and significantly increased the risk by four-fold during 4-5 years of follow-up [HR=3.809 95[percnt]CI(1.628-8.912); p=0.002]. We did not identify meaningful associations for disability progression with MV. Conclusions: Our results provide compelling evidence of the clinical utility of monitoring retinal atrophy by OCT, for predicting the likelihood of disability progression in MS patients over time.

披露:Martinez-Lapiscina博士已经收到个人活动与生原体补偿Idec和Genzyme演讲者。•阿诺博士没有披露。威尔逊博士没有披露。Saidha博士已经收到个人活动与医疗补偿Logix CME项目发展的神经学、和已经收到个人活动与补偿轴突Advisors LLC。Saidha博士收到Preiningerova博士的研究支持已收到个人活动与补偿Idec,诺华,Teva神首页经科学。Preiningerova博士收到生原体研究支持Idec。Oberwahrenbrock博士已经收到个人活动与补偿Teva神经科学。布兰德博士已经收到个人活动与补偿Meedical(医疗GmbH Medizintechnik)共同创始人和董事。布兰德博士已经收到个人补偿活动与海德堡工程作为一个演讲者。布兰德博士recei Pablo博士没有披露。Guerrieri博士没有披露。 Dr. Gonzalez has received personal compensation for activities with Novartis and Merck. Dr. Outteryk has received personal compensation for activities with Novartis, Biogen Idec, Genzyme-Sanofi, Merck-Serono, and Teva. Dr. Mueller has nothing to disclose. Dr. Albrecht has received personal compensation for activities with Biogen, Novartis, TEVA, IPSEN, Merz, Esai, GSK. Dr. Albrecht has received research support from Biogen, Merz and Novartis. Dr. Chan has nothing to disclose. Dr. Lukas has received personal compensation for activities with Genzyme, Biogen, and Heidelberg Engineering as a speaker. Dr. Balk has nothing to disclose. Dr. Fraser has nothing to disclose. Dr. Frederiksen Battisti has received personal compensation for activities with Biogen Idec, Merck Serono, Sanofi-Aventis, Genzyme, Teva, Novartis, and Takeda. Dr. Resto has nothing to disclose. Dr. Frohman has received personal compensation for activities with Novartis, Genzyme, and Acorda. Dr. Cordano has nothing to disclose. Dr. Zubizarreta has nothing to disclose. Dr. Sanchez-Dalmau has nothing to disclose. Dr. Saiz has received personal compensation for consulting services and speaking from Bayer-Schering, Merck-Serono, Biogen Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd and Novartis. Dr. Bermel has received personal compensation for activities with Biogen Idec., Novartis, Teva, Genzyme and Questcor. Dr. Klistorner has received personal compensation for activities with Biogen as a consultant. Dr. Petzold has received (royalty or license fee or contractual rights) payments from VUMC. Dr. Schippling has received personal compensation for activities with Biogen, Genzyme/Sanofi, Merck Serono, Novartis, and TEVA as a consultant and speaker. I received an honorarium for speaking at the University of Alberta grand rounds directly from Novartis . Dr. Aktas has received personal compensation for activities with Bayer, Biogen, Chugai, Genzyme, Novartis, Roche, Teva, Medimmune as an advisor/honoraria. Dr. Vermersch has received personal compensation for activities with Biogen Idec, Sanofi, Bayer, Novartis, Merck Serono, GlaxoSmithKline, and Almirall. Dr. Vermersch has received research support from Biogen Idec, Sanofi, Bayer, and Merck Serono. Dr. Oreja-Guevara has nothing to disclose. Dr. Comi has received personal compensation for activities with Teva, Novartis, Genzyme, Merck Serono, Biogen, Bayer, Actelion, Almirall, and Serono Symposia International Foundation. Dr. Leocani has received personal compensation for activities with AbbVie, Almirall, Biogen, Excemed, Genzyme, EMD Serono, and Novartis. Dr. Garcia-Martin has nothing to disclose. Dr. Paul has received personal compensation for activities with Teva Neuroscience, Sanofi-Aventis Pharmaceuticals, Inc., Bayer Schering Pharma, Merck Serono, Biogen Idec, Medimmune, and Novartis. Dr. Havrdova has received research support from Biogen Idec and Merck Serono. Dr. Frohman has received personal compensation for activities with Novartis, Genzyme, Acorda and Teva Neuroscience as a speaker and consultant. Dr. Balcer has received personal compensation for activities with Biogen Idec and Genzyme as a consultant. Inception Sciences, Mylan Pharma, Medimmune, Bionure. Inception Sciences. Inception Sciences, Biogen, Novartis. Dr. Peter A. Calabresi has received personal compensation for activities with Abbott and Vertex as a consultant. Dr. Calabresi has received research support from Novartis, MedImmune and Biogen. Dr. Villoslada has received personal compensation in an editorial capacity for Treatment Options in Neurology.